In advanced stage NPC patients, Survivin and VEGF high expression render tumor cell resistant to the conventional therapies including radiotherapy and/or chemotherapy and may need more systemic treatment or targeted antagonists of survivin and VEGF therapy. This evidence concerns the gene BIRC5 and nasopharyngeal carcinoma.